Fig. 1 · Structure

Documents & Downloads

Edaravone (MCI-186)

Cat. No. A11725 CAS 89-25-8
Edaravone is a free radical scavenger with diverse protective effects that inhibits production of reactive oxygen species, apoptosis and the lipoxygenase system.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
HBMEC-2 EC50 4.61 μM Neuroprotective activity against H2O2-induced cell damage in human HBMEC2 cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay [PMID: 31541868]
PC-12 EC50 9.2 μM Neuroprotective activity against 12.5 mM glutamate-induced toxicity in rat PC12 cells assessed as cell viability after 24 hrs by MTT assay [PMID: 28394604]
Platelet IC50 0.25 mM Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method [PMID: 22827516]
Platelet IC50 0.85 mM Inhibition of adenosine diphosphate-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method [PMID: 22827516]
SH-SY5Y EC50 3.75 μM Neuroprotective activity against H2O2-induced cell damage in human SH-SY5Y cells assessed as increase in cell viability preincubated for 24 hrs followed by H2O2 addition and measured after 4 hrs by MTT assay [PMID: 31541868]

In Vitro Studies

In primary SGNs, Edaravone added to the medium before glutamate treatment increased MTT cell viability compared with glutamate alone. Edaravone administered after glutamate treatment yielded higher viability at the earliest tested time point, while later treatment produced no significant improvement. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Edaravone Pretreatment in Primary SGNs

Cell-based study · primary SGNs [1]

Primary SGNs received Edaravone in the medium for 20 min before glutamate treatment. MTT cell viability was 75% with 500 μM Edaravone, compared with 32% with glutamate alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell viability was detected by MTT assayCell viability 20 min before glutamate treatment: 250 μM: 48%; 500 μM: 75%; 750 μM: 78%[1]

Literature-Reported Treatment Conditions

Treatment concentration
250 μM, 500 μM, and 750 μM
Exposure duration
for 20 min before glutamate treatment
Method
added to the medium
Co-treatment
Other interventions in this design: glutamate 2 mM. Compound effect isolated by the comparison: versus glutamate-treated group.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Edaravone

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.2. Primary Cultures of Rat SGNs (S13); 2. Materials and Methods > 2.3. Drug Treatment (S15, S17); 2. Materials and Methods > 2.4. Assessment of Cell Viability by MTT and Trypan Blue Staining (S20); 3. Results > 3.3. Edaravone Alleviated the Decrease of Cell Viability Caused by Glutamate (S70, S71); Figure 4 legend (S117, S118)

Cell viability was detected by MTT assay: Cell viability was detected by MTT assay; comparator: glutamate alone — 3. Results > 3.3. Edaravone Alleviated the Decrease of Cell Viability Caused by Glutamate (S70, S71); Figure 4 legend (S117)

Edaravone After Glutamate Treatment in Primary SGNs

Cell-based study · primary SGNs [1]

500 μM edaravone was added to the medium 2 h, 6 h, or 12 h after glutamate treatment. Treatment of edaravone at the time point of 2 h after glutamate achieved satisfying protection for SGNs against glutamate-induced cytotoxicity. But there was no significant improvement in cell viability when treated at later time points.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell viability was detected by MTT assayCell viability 500 μM edaravone after glutamate treatment: 2 h: 49%; 6 h: 35%; 12 h: 33%[1]

Literature-Reported Treatment Conditions

Treatment concentration
500 μM
Exposure duration
2 h, 6 h, or 12 h after glutamate treatment
Method
added to the medium
Co-treatment
Other interventions in this design: glutamate 2 mM. Compound effect isolated by the comparison: versus glutamate-treated group.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Edaravone

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.2. Primary Cultures of Rat SGNs (S13); 2. Materials and Methods > 2.4. Assessment of Cell Viability by MTT and Trypan Blue Staining (S20); 3. Results > 3.2. Edaravone Performed Both Preventative and Therapeutic Effects against Toxicity of Glutamate (S63); 3. Results > 3.3. Edaravone Alleviated the Decrease of Cell Viability Caused by Glutamate (S74, S75, S77); Figure 3 legend (S110); Figure 5 legend (S121, S122)

Cell viability was detected by MTT assay: Cell viability was detected by MTT assay; comparator: glutamate alone — 3. Results > 3.3. Edaravone Alleviated the Decrease of Cell Viability Caused by Glutamate (S74, S75, S77); Figure 5 legend (S121)

In Vivo Studies

In SCID mice intracranially injected with luciferase-expressing BTSC73, intraperitoneal Edaravone alone delayed tumor formation and decreased luciferase activity compared with control mice. In adult female Sprague-Dawley rats with a 6-OHDA lesion, intravenous Edaravone significantly reduced amphetamine-induced rotations compared with rats without Edaravone administration. [2,3]

Tumor formation in mice bearing intracranial BTSC73

Animal study · Luciferase-expressing BTSC73 was intracranially injected into SCID mice [2]

SCID mice intracranially injected with luciferase-expressing BTSC73 received Edaravone at 50 mg/kg intraperitoneally. Edaravone alone and IR alone delayed tumor formation, with ∼5-fold decrease in luciferase activity compared to control mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
luciferase activityluciferase activity ∼5-fold decrease in luciferase activity[2]

Conditions shared by the study groups

Route
intraperitoneally
Treatment course
Six days post BTSC injection; every day until mice were sacrificed
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Edaravone 50 mg/kgvehicle controlEdaravone alone and IR alone delayed tumor formation, with ∼5-fold decrease in luciferase activity compared to control mice.[2]
Edaravone 50 mg/kg
Model: Luciferase-expressing BTSC73 was intracranially injected into SCID mice
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Edaravone

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Edaravone treatment sensitizes BTSCs and GB tumors to IR-induced cell death (S111, S117, S118); Experimental procedures > Stereotaxic injections (S146)

luciferase activity: luciferase activity; comparator: vehicle control — Results > Edaravone treatment sensitizes BTSCs and GB tumors to IR-induced cell death (S118)

Edaravone 50 mg/kg · Results > Edaravone treatment sensitizes BTSCs and GB tumors to IR-induced cell death (S117, S118); Experimental procedures > Stereotaxic injections (S146)

Edaravone and Amphetamine-Induced Rotations in Lesioned Rats

Animal study · adult female Sprague-Dawley rats; 6-OHDA lesion [3]

Adult female Sprague-Dawley rats received 250 mg/kg Edaravone intravenously at 30 minutes after 6-OHDA lesion. Amphetamine-induced rotations were significantly reduced compared with rats without Edaravone administration.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
number of amphetamine-induced rotationsReported result Rats receiving 250 mg/kg of edaravone-administration at 30 minutes after 6-OHDA lesion showed a significant reduction of the rotational number (3.8 ± 0.9 and 2.3 ± 0.7 turns/hour at 1 and 2 weeks).[3]

Conditions shared by the study groups

Route
intravenously administered slowly from the right femoral vein
Treatment course
at 30 minutes after 6-OHDA lesion
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Edaravone 250 mg/kgintravenous saline-infusionRats receiving 250 mg/kg of edaravone-administration at 30 minutes after 6-OHDA lesion showed a significant reduction of the rotational number (3.8 ± 0.9 and 2.3 ± 0.7 turns/hour at 1 and 2 weeks).[3]
Edaravone 250 mg/kg
Model: adult female Sprague-Dawley rats; 6-OHDA lesion
Reported limits: Not stated in the sentences used: vehicle. Removed after verification: value.
Methods and source locations

Compound reported in the paper: Edaravone

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > In vivo model of Parkinson's disease > Subjects (S26); Methods > In vivo model of Parkinson's disease > Surgical procedures (S29, S31); Methods > In vivo model of Parkinson's disease > Behavioral testing (S32); Results > Behavioral analyses in vivo (S60, S61); Figure 4 legend (S95)

number of amphetamine-induced rotations: number of amphetamine-induced rotations; comparator: intravenous saline-infusion — Results > Behavioral analyses in vivo (S60, S61)

Edaravone 250 mg/kg · Methods > In vivo model of Parkinson's disease > Surgical procedures (S31); Results > Behavioral analyses in vivo (S61)

Specifications

Manufacturer Adooq Bioscience
CAS Number 89-25-8
Formula C10H10N2O
Molecular Weight 174.2
Synonyms Radicut; MCI-186
SMILES
CC1=NN(C(=O)C1)C2=CC=CC=C2

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 31 mg/mL (177.95 mM)
Water Insoluble
Ethanol 31 mg/mL (177.95 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Bai X, Zhang C, Chen A, et al. Protective Effect of Edaravone on Glutamate-Induced Neurotoxicity in Spiral Ganglion Neurons. Neural Plast (2016). PMID: 27957345 DOI: 10.1155/2016/4034218 Source material
  2. [2] Burban A, Sharanek A, Hernandez-Corchado A, et al. Targeting glioblastoma with a brain-penetrant drug that impairs brain tumor stem cells via NLE1-Notch1 complex. Stem Cell Reports (2024). PMID: 39423824 DOI: 10.1016/j.stemcr.2024.09.007 Source material
  3. [3] Yuan WJ, Yasuhara T, Shingo T, et al. Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons. BMC Neurosci (2008). PMID: 18671880 DOI: 10.1186/1471-2202-9-75 Source material

Added to your cart

View Cart Checkout
Loading...